1. Ligustrazine Suppresses Platelet-Derived Growth Factor-BB-Induced Pulmonary Artery Smooth Muscle Cell Proliferation and Inflammation by Regulating the PI3K/AKT Signaling Pathway.
- Author
-
Huang, Huiping, Kong, Lingjin, Luan, Shaohua, Qi, Chuanzong, and Wu, Fanrong
- Subjects
- *
PULMONARY hypertension prevention , *INFLAMMATION prevention , *LUNG anatomy , *TISSUE analysis , *MEDICINAL plants , *IN vivo studies , *SILDENAFIL , *CENTRAL venous pressure , *CATTLE , *CELL culture , *ALKALOIDS , *ANIMAL experimentation , *PULMONARY hypertension , *RIGHT ventricular hypertrophy , *FLUOROIMMUNOASSAY , *WESTERN immunoblotting , *ONE-way analysis of variance , *PULMONARY artery , *VASCULAR smooth muscle , *CELLULAR signal transduction , *PLANT roots , *RATS , *PATIENT monitoring , *GENE expression , *CELL survival , *CELL cycle , *T-test (Statistics) , *CELL proliferation , *TRANSFERASES , *RESEARCH funding , *DESCRIPTIVE statistics , *PLANT extracts , *HEMODYNAMICS , *INFLAMMATORY mediators , *BIOLOGICAL assay , *CELL separation , *DATA analysis software , *PLATELET-derived growth factor , *PHOSPHORYLATION , *RADIOIMMUNOASSAY - Abstract
Pulmonary arterial hypertension (PAH) is a serious pulmonary vascular disease. Excessive proliferation of pulmonary artery smooth muscle cells (PASMCs) plays an important role in the course of this disease. Ligustrazine is an alkaloid monomer extracted from the rhizome of the herb Ligusticum chuanxiong. It is often used to treat cardiovascular diseases, but its effect on PAH has rarely been reported. This study aims to explore the protective effect and mechanism of ligustrazine on PAH. In the in vivo experiment, monocrotaline (MCT) was used to induce PAH in rats, and then ligustrazine (40, 80, 160 mg/kg/day) or sildenafil (25 mg/kg/day) was administered. Four weeks later, hemodynamic changes, right ventricular hypertrophy index, lung morphological characteristics, inflammatory factors, phosphoinositide 3-kinase (PI3K), and AKT expression were evaluated. In addition, primary rat PASMCs were extracted by the tissue adhesion method, a proliferation model was established with platelet-derived growth factor-BB (PDGF-BB), and the cells were treated with ligustrazine to investigate its effects on cell proliferation, inflammation, and cell cycle distribution. The results indicate that ligustrazine can markedly alleviate right ventricular systolic pressure, right ventricular hypertrophy, pulmonary vascular remodeling, and inflammation caused by MCT, and that it decreased PI3K and AKT phosphorylation expression. Moreover, ligustrazine can inhibit the proliferation and inflammation of PASMCs and arrest the progression of G0/G1 to S phase through the PI3K/AKT signaling pathway. Therefore, we conclude that ligustrazine may inhibit the proliferation and inflammation of PASMCs by regulating the activation of the PI3K/AKT signaling pathway, thereby attenuating MCT-induced PAH in rats. Collectively, these findings suggest that ligustrazine may be a promising therapeutic for PAH. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF